Is Nurix Therapeutics, Inc. (NRIX) a Buy, Sell, or Hold?
NASDAQ : NRIX
Nurix Therapeutics, Inc.
$23.38 USD
-$0.36 (-1.52%)
- Volume
- 833.25K
- Average Volume
- 1.99M
- Market Capitalization
- $2.43B
- P/E Ratio
- -6.78
- Dividend Yield
- 0.00%
- Price Target
- $34.00
- Year High
- $25.09
- Year Low
- $8.20
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.34
Company Overview
NASDAQ
Arthur T. Sands
Biotechnology
Healthcare
NRIX
317
US
USD
Liquidity Metrics
0.14
6.34
6.34
0.94
0.00
Sales & Valuation
$83.98M
66.00
6.45
-7.97
-2.74
Profitability
-$3.05
-$264.46M
-928.44%
-929.18%
-76.09%
-63.74%
P/E Metrics
-6.78
0.26
0.26
Analyst Price Target & Rating
$34.00
$45.00
$28.00
1/5
19 Analysts
-31.24%
Financial Health Scores
4.89
2/9
$384.46M
$535.54M
$132.91M
-$341.62M
Key Metrics (TTM)
$2.42B
65.74
-7.56
6.34
-76.09%
-77.32%
-13.14%
-12.55%
-46 days
Company Executives
| Name | Title |
|---|---|
| Gwenn Hansen | Chief Scientific Officer |
| John Kuriyan | Founder & Member of Scientific Advisory Board |
| Arthur Weiss | Founder & Member of Scientific Advisory Board |
| Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer |
| Jason Kantor | Chief Business Officer |
| Christopher Phelps | Senior Vice President & Head of Early Drug Discovery |
| Johannes Van Houte | Chief Financial Officer |
| Pasit Phiasivongsa | Chief Technical Officer |
| Rita Kwong | Senior Accounting Manager |
| Arthur T. Sands | Chief Executive Officer, President & Director |
Poll Results
No votes yet today — be the first to share your view!
About Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It i ... s also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum
2026-07-23 15:21:04
RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.
2026-07-21 16:01:00
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the closing of its previously announced global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Amova Asset Management Americas Inc. Sells 109,408 Shares of Nurix Therapeutics, Inc. $NRIX
2026-07-21 03:16:01
Amova Asset Management Americas Inc. cut its position in shares of Nurix Therapeutics, Inc. (NASDAQ: NRIX) by 8.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,181,146 shares of the company's stock after selling 109,408 shares during
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
2026-07-15 13:10:36
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
2026-07-09 18:26:04
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to a loss of $0.52 per share a year ago.
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-09 16:01:00
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment
Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline
2026-07-01 11:01:05
Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade
2026-07-01 10:55:14
The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Frequently Asked Questions
-
What is the current Nurix Therapeutics, Inc. (NRIX) stock price?
-
Nurix Therapeutics, Inc.(NASDAQ:NRIX) stock price is $23.38 in the last trading session. During the trading session, NRIX stock reached the peak price of $25.085 while $8.195 was the lowest point it dropped to. The percentage change in NRIX stock occurred in the recent session was --1.52% while the dollar amount for the price change in NRIX stock was -$0.36.
-
NRIX's industry and sector of operation?
-
The NASDAQ listed NRIX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NRIX?
-
Gwenn Hansen | Chief Scientific Officer
John Kuriyan | Founder & Member of Scientific Advisory Board
Arthur Weiss | Founder & Member of Scientific Advisory Board
Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer
Jason Kantor | Chief Business Officer -
How many employees does NRIX have?
-
Number of NRIX employees currently stands at 317. NRIX operates from 1600 Sierra Point Parkway, Brisbane, CA 94005, US.
-
Link for NRIX official website?
-
Official Website of NRIX is: https://www.nurixtx.com
-
How do I contact NRIX?
-
NRIX could be contacted at phone #415 660 5320 and can also be accessed through its website. NRIX operates from 1600 Sierra Point Parkway, Brisbane, CA 94005, US.
-
How many shares of NRIX are traded daily?
-
The average number of NRIX shares traded daily for last 3 months was 1.99M.
-
What is the market cap of NRIX currently?
-
The market value of NRIX currently stands at $2.43B with its latest stock price at $23.38